EXHIBIT 99.1
Shire Pharmaceuticals Group plc | ![]() |
Shire to present at Merrill Lynch Healthcare Conference, New York
Basingstoke, UK – 2 February 2004– Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that Chief Executive Matthew Emmens will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York on Tuesday, 3 February 2004, at 4:10 pm Eastern Time (9:10 pm GMT). Investors may access a live audio webcast of the presentation atwww.shire.com.
For further information please contact:
Investor Relations
Souheil Salah | +44 1256 894 160 |
Notes to editors | |
Shire Pharmaceuticals Group plc |
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com